Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 19/20 | 0.67 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.43 |
| ▸ | BPTF | Q12830 | 2/20 | 0.43 |
| ▸ | BRD1 | O95696 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.43 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.43 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.43 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30831142 | 0.91 | KAT2B (0.65) | KAT2B | |
| SCHEMBL17571681 | 0.82 | KAT2B (1.00) | KAT2BKAT2A | |
| SCHEMBL30830531 | 0.74 | KAT2B (0.52) | KAT2BBRD9BPTFBRD1ACHE | |
| SCHEMBL30830660 | 0.72 | KAT2B (0.46) | KAT2BBRD9BPTFBRD1ACHE | |
| SCHEMBL30830474 | 0.72 | KAT2B (0.62) | KAT2BBRD9BPTFBRD1ACHE | |
| SCHEMBL17571551 | 0.72 | KAT2B (1.00) | KAT2BKAT2A | |
| SCHEMBL30830559 | 0.71 | KAT2B (0.79) | KAT2BBRD9BPTFBRD1ACHE | |
| SCHEMBL30830592 | 0.71 | KAT2B (0.79) | KAT2BBRD9BPTFBRD1ACHE | |
| SCHEMBL31091734 | 0.70 | KAT2B (0.81) | KAT2BBPTFKAT2ASETDB1 | |
| SCHEMBL19377001 | 0.70 | KAT2B (0.67) | KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |